Compare STRIDES PHARMA SCIENCE with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs FDC LTD. - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE FDC LTD. STRIDES PHARMA SCIENCE/
FDC LTD.
 
P/E (TTM) x 7.7 18.0 43.0% View Chart
P/BV x 0.9 2.7 34.2% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 STRIDES PHARMA SCIENCE   FDC LTD.
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
FDC LTD.
Mar-18
STRIDES PHARMA SCIENCE/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs1,147319 359.6%   
Low Rs642164 391.5%   
Sales per share (Unadj.) Rs317.261.6 514.6%  
Earnings per share (Unadj.) Rs7.89.9 78.8%  
Cash flow per share (Unadj.) Rs25.112.0 209.4%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs274.373.2 374.8%  
Shares outstanding (eoy) m89.50174.40 51.3%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x2.83.9 72.0%   
Avg P/E ratio x114.024.3 469.7%  
P/CF ratio (eoy) x35.720.2 176.9%  
Price / Book Value ratio x3.33.3 98.8%  
Dividend payout %25.50-   
Avg Mkt Cap Rs m80,05842,118 190.1%   
No. of employees `0002.55.5 45.3%   
Total wages/salary Rs m4,3412,167 200.3%   
Avg. sales/employee Rs Th11,325.81,943.7 582.7%   
Avg. wages/employee Rs Th1,731.4391.7 442.0%   
Avg. net profit/employee Rs Th280.1313.7 89.3%   
INCOME DATA
Net Sales Rs m28,39410,751 264.1%  
Other income Rs m941510 184.6%   
Total revenues Rs m29,33411,260 260.5%   
Gross profit Rs m3,9652,267 174.9%  
Depreciation Rs m1,540351 438.4%   
Interest Rs m1,96214 14,017.1%   
Profit before tax Rs m1,4032,411 58.2%   
Minority Interest Rs m0-5 0.0%   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97671 14.5%   
Profit after tax Rs m7021,735 40.5%  
Gross profit margin %14.021.1 66.2%  
Effective tax rate %6.927.8 24.9%   
Net profit margin %2.516.1 15.3%  
BALANCE SHEET DATA
Current assets Rs m24,8367,213 344.3%   
Current liabilities Rs m18,9932,104 902.8%   
Net working cap to sales %20.647.5 43.3%  
Current ratio x1.33.4 38.1%  
Inventory Days Days7154 130.2%  
Debtors Days Days11328 409.0%  
Net fixed assets Rs m34,2896,865 499.5%   
Share capital Rs m895175 510.8%   
"Free" reserves Rs m23,65112,586 187.9%   
Net worth Rs m24,54612,761 192.3%   
Long term debt Rs m15,5136 258,553.3%   
Total assets Rs m65,43715,041 435.1%  
Interest coverage x1.7173.2 1.0%   
Debt to equity ratio x0.60 134,420.2%  
Sales to assets ratio x0.40.7 60.7%   
Return on assets %4.111.6 35.0%  
Return on equity %2.913.6 21.0%  
Return on capital %6.919.0 36.4%  
Exports to sales %012.3 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA1,327 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,6971,889 831.0%   
Fx outflow Rs m7350-   
Net fx Rs m14,9621,889 792.1%   
CASH FLOW
From Operations Rs m1,8711,498 124.8%  
From Investments Rs m5,826201 2,897.0%  
From Financial Activity Rs m-10,157-1,694 599.5%  
Net Cashflow Rs m-2,61510 -25,387.3%  

Share Holding

Indian Promoters % 27.7 68.9 40.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 4.7 804.3%  
FIIs % 8.6 7.5 114.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 19.0 136.3%  
Shareholders   56,241 23,730 237.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   DIVIS LABORATORIES  WOCKHARDT  AUROBINDO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 186 Points Higher; Energy and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day on a positive note.

Related Views on News

FDC LTD. Announces Quarterly Results (2QFY20); Net Profit Up 45.4% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, FDC LTD. has posted a net profit of Rs 627 m (up 45.4% YoY). Sales on the other hand came in at Rs 3 bn (up 28.8% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

FDC LTD. Announces Quarterly Results (1QFY20); Net Profit Up 2.4% (Quarterly Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

For the quarter ended June 2019, FDC LTD. has posted a net profit of Rs 523 m (up 2.4% YoY). Sales on the other hand came in at Rs 3 bn (up 17.9% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

FDC LTD. Announces Quarterly Results (4QFY19); Net Profit Up 6.8% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, FDC LTD. has posted a net profit of Rs 337 m (up 6.8% YoY). Sales on the other hand came in at Rs 3 bn (down 0.6% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Nov 19, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS